Journal DOI 10.68956/journal.human-performance-futures

Creative Commons source reading · Machine learning for performance

Advancing Genitourinary Cancer Surgery: The Role of Artificial Intelligence and Robotics

Katsimperis S; Kostakopoulos N; Bellos T; Spinos T; Peteinaris A; Tzelves L; Kostakopoulos A; Skolarikos A

Originally published in J Clin Med · 2026-05-17

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

AbstractThe convergence of artificial intelligence and robotic surgery is redefining the management of genitourinary cancers by enhancing diagnostic accuracy, surgical precision, and training efficiency. This narrative review explores recent advancements in artificial intelligence applications across the cancer care continuum, with a focus on prostate, kidney, and bladder malignancies. Artificial intelligence tools, particularly those based on machine learning and deep learning, have demonstrated strong performance in analyzing imaging data, segmenting tumors, predicting pathological features, and supporting clinical decision-making. Intraoperatively, artificial intelligence enables skill assessment, personalized feedback, and real-time navigation by processing data from surgical videos and robotic system sensors. Augmented reality…

7. Conclusions

Artificial intelligence is increasingly reshaping the landscape of robotic surgery in genitourinary oncology, offering tools that enhance imaging interpretation, intraoperative navigation, surgical performance assessment, and procedural planning. The integration of augmented reality, advanced deep learning models, and single-port platforms is driving a more precise, personalized, and minimally invasive approach to cancer surgery. Although many of these technologies remain under active investigation, early results are promising. Continued validation and broader clinical adoption will be essential to realize their full potential in improving outcomes and reducing disparities in urologic cancer care.

Editorial reading guide

  • What data created and tested the model, and was evaluation independent?
  • What is the cost of a false positive, false negative or out-of-distribution decision?